
With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine …

Sanofi interest in making a big acquisition has been clear for the last few years and its struggles to solidify …

Bioverativ, a biotech company that develops therapies for rare blood disorders, announced the appointment of Tim Harris as Executive Vice …

Biogen has announced that Bioverativ will be the name of the standalone spin-off of its haemophilia and other blood disorders …

